Dyadic International (NASDAQ:DYAI) Announces Quarterly Earnings Results

Dyadic International (NASDAQ:DYAI) announced its earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01), Zacks reports. The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $1.00 million. Dyadic International had a negative net margin of 347.92% and a negative return on equity of 116.14%. During the same quarter last year, the business earned ($0.07) earnings per share.

Dyadic International Price Performance

DYAI stock traded down $0.09 during mid-day trading on Thursday, reaching $1.27. 136,959 shares of the company’s stock were exchanged, compared to its average volume of 57,130. The company has a market cap of $37.13 million, a price-to-earnings ratio of -4.53 and a beta of 0.73. Dyadic International has a 12-month low of $1.13 and a 12-month high of $2.67. The stock’s 50 day moving average is $1.56 and its 200 day moving average is $1.58. The company has a debt-to-equity ratio of 1.29, a current ratio of 5.54 and a quick ratio of 5.54.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a research note on Monday, July 8th.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.